William Blair Predicts Higher Earnings for Ovid Therapeutics

Ovid Therapeutics (NASDAQ:OVID) – William Blair increased their FY2025 earnings per share estimates for Ovid Therapeutics in a research note issued on Wednesday, August 13th. William Blair analyst M. Minter now expects that the company will post earnings of ($0.50) per share for the year, up from their prior estimate of ($0.58). William Blair currently has a “Strong-Buy” rating on the stock. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.40) per share. William Blair also issued estimates for Ovid Therapeutics’ Q1 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.18) EPS, Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($0.72) EPS, FY2027 earnings at ($1.01) EPS, FY2028 earnings at ($1.13) EPS and FY2029 earnings at ($1.23) EPS.

Ovid Therapeutics (NASDAQ:OVID) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.10. Ovid Therapeutics had a negative return on equity of 58.87% and a negative net margin of 574.44%. The business had revenue of $6.27 million for the quarter, compared to the consensus estimate of $0.09 million.

A number of other research analysts also recently commented on the company. Wall Street Zen upgraded Ovid Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. B. Riley restated a “buy” rating and issued a $3.00 target price on shares of Ovid Therapeutics in a research note on Friday, August 8th. Finally, HC Wainwright lowered their target price on Ovid Therapeutics from $2.00 to $1.50 and set a “buy” rating on the stock in a research note on Tuesday, May 27th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Ovid Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $3.10.

Ovid Therapeutics Stock Performance

Shares of NASDAQ OVID opened at $0.97 on Monday. The business’s 50-day moving average price is $0.45 and its two-hundred day moving average price is $0.42. The company has a debt-to-equity ratio of 0.23, a current ratio of 4.72 and a quick ratio of 4.72. Ovid Therapeutics has a one year low of $0.24 and a one year high of $1.47. The company has a market capitalization of $68.98 million, a P/E ratio of -1.83 and a beta of 0.20.

Institutional Trading of Ovid Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE lifted its position in shares of Ovid Therapeutics by 49.7% in the fourth quarter. Bank of America Corp DE now owns 56,733 shares of the company’s stock worth $53,000 after buying an additional 18,841 shares during the last quarter. Velan Capital Investment Management LP acquired a new stake in shares of Ovid Therapeutics in the fourth quarter worth about $65,000. XTX Topco Ltd acquired a new stake in shares of Ovid Therapeutics in the first quarter worth about $29,000. Renaissance Technologies LLC lifted its position in shares of Ovid Therapeutics by 142.0% in the fourth quarter. Renaissance Technologies LLC now owns 107,700 shares of the company’s stock worth $101,000 after buying an additional 63,200 shares during the last quarter. Finally, Nuveen LLC acquired a new stake in shares of Ovid Therapeutics in the first quarter worth about $37,000. Institutional investors and hedge funds own 72.24% of the company’s stock.

About Ovid Therapeutics

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.